<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">pulmo</journal-id><journal-title-group><journal-title xml:lang="ru">Пульмонология</journal-title><trans-title-group xml:lang="en"><trans-title>PULMONOLOGIYA</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">0869-0189</issn><issn pub-type="epub">2541-9617</issn><publisher><publisher-name>Scientific and Practical Journal “PULMONOLOGIYA” LLC</publisher-name></publisher></journal-meta><article-meta><article-id custom-type="elpub" pub-id-type="custom">pulmo-3101</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОБЗОРЫ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>REVIEW</subject></subj-group></article-categories><title-group><article-title>Применение фиксированных комбинаций ингаляционных кортикостероидов и длительно действующих β2-агонистов в лечении бронхиальной астмы</article-title><trans-title-group xml:lang="en"><trans-title>Fixed combinations of inhaled steroids and long-acting β2-agonists in bronchial asthma treatment</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Чучалин</surname><given-names>А. Г.</given-names></name><name name-style="western" xml:lang="en"><surname>Chuchalin</surname><given-names>A. G.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Москва</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Калманова</surname><given-names>Е. Н.</given-names></name><name name-style="western" xml:lang="en"><surname>Kalmanova</surname><given-names>E. N.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Москва</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Айсанов</surname><given-names>З. Р.</given-names></name><name name-style="western" xml:lang="en"><surname>Aisanov</surname><given-names>Z. R.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Москва</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Стулова</surname><given-names>О. Ю.</given-names></name><name name-style="western" xml:lang="en"><surname>Stoulova</surname><given-names>O. Yu.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Москва</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Беда</surname><given-names>М. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Beda</surname><given-names>M. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Москва</p></bio><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff xml:lang="ru" id="aff-1"><institution>НИИ пульмонологии М3 РФ;&#13;
Глаксо Вэллком</institution><country>Russian Federation</country></aff><pub-date pub-type="collection"><year>2000</year></pub-date><pub-date pub-type="epub"><day>30</day><month>03</month><year>2000</year></pub-date><volume>0</volume><issue>1</issue><fpage>81</fpage><lpage>85</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Чучалин А.Г., Калманова Е.Н., Айсанов З.Р., Стулова О.Ю., Беда М.В., 2000</copyright-statement><copyright-year>2000</copyright-year><copyright-holder xml:lang="ru">Чучалин А.Г., Калманова Е.Н., Айсанов З.Р., Стулова О.Ю., Беда М.В.</copyright-holder><copyright-holder xml:lang="en">Chuchalin A.G., Kalmanova E.N., Aisanov Z.R., Stoulova O.Y., Beda M.V.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://journal.pulmonology.ru/pulm/article/view/3101">https://journal.pulmonology.ru/pulm/article/view/3101</self-uri><abstract><p>.</p></abstract></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Adkins J.C., McTavish D. Salmeterol: a review of its pharmacological properties and clinical efficacy in management of children with asthma// Drugs.— 1997.— Vol.54.— P. 331— 354.</mixed-citation><mixed-citation xml:lang="en">Adkins J.C., McTavish D. Salmeterol: a review of its pharmacological properties and clinical efficacy in management of children with asthma// Drugs.— 1997.— Vol.54.— P. 331— 354.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Bateman E.D., Britton М ., Carrillo J., et al. Salmelerol/fluticasone combination inhaler: a new, effective and well tolerated treatment for asthma//Clin. Drug Invest.— 1998.— Vol.16.— P. 193—201.</mixed-citation><mixed-citation xml:lang="en">Bateman E.D., Britton М ., Carrillo J., et al. Salmelerol/fluticasone combination inhaler: a new, effective and well tolerated treatment for asthma//Clin. Drug Invest.— 1998.— Vol.16.— P. 193—201.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Broaden R.N., Faulds D. Salmeterol xinafoate: a review of its pharmacological properties and therapeutic potential in reversible obstructive airways disease//Drugs.— 1991.— Vol.42P. 895—912.</mixed-citation><mixed-citation xml:lang="en">Broaden R.N., Faulds D. Salmeterol xinafoate: a review of its pharmacological properties and therapeutic potential in reversible obstructive airways disease//Drugs.— 1991.— Vol.42P. 895—912.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Chapman K.R., Ringdal N„ Backer V., et al. Salmeterol and fluticasone propionate (50/250mcg) administered via combination Discus inhaler: as effective as when given via separate Diskus inhalers//Can. Respir. J.— 1999.— Vol.6, N .I.— P.45—51.</mixed-citation><mixed-citation xml:lang="en">Chapman K.R., Ringdal N„ Backer V., et al. Salmeterol and fluticasone propionate (50/250mcg) administered via combination Discus inhaler: as effective as when given via separate Diskus inhalers//Can. Respir. J.— 1999.— Vol.6, N .I.— P.45—51.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Chung K.F. The complementary role of glucocorticosteroids and long-acting (Vadrenergic agonists// Allergy.— 1998.— Vol. 53, Suppl.42.— P.7—13.</mixed-citation><mixed-citation xml:lang="en">Chung K.F. The complementary role of glucocorticosteroids and long-acting (Vadrenergic agonists// Allergy.— 1998.— Vol. 53, Suppl.42.— P.7—13.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Coutts J.A.P., Gibson N.A., Paton J.Y. Measuring compliance with inhaled medication in asthma//Arch. Dis. Child.— 1992.— Vol.67.— P.332—333.</mixed-citation><mixed-citation xml:lang="en">Coutts J.A.P., Gibson N.A., Paton J.Y. Measuring compliance with inhaled medication in asthma//Arch. Dis. Child.— 1992.— Vol.67.— P.332—333.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Dahl R. Salmeterol and fluticasone propionate in the treatment of asthma symptoms//Eur. Resp. Rev.— 1997.— №.7.— Vol.P. 338—343.</mixed-citation><mixed-citation xml:lang="en">Dahl R. Salmeterol and fluticasone propionate in the treatment of asthma symptoms//Eur. Resp. Rev.— 1997.— №.7.— Vol.P. 338—343.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Davies B., Brooks G., Devoy M. The efficacy and safety of salmeterol compared to theophylline: meta-analysis of nine control stiudies//Respir. Med.— 1998.— Vol.92.— P.256— 263.</mixed-citation><mixed-citation xml:lang="en">Davies B., Brooks G., Devoy M. The efficacy and safety of salmeterol compared to theophylline: meta-analysis of nine control stiudies//Respir. Med.— 1998.— Vol.92.— P.256— 263.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Edwards T., Gross G., Mitchell D., et al. The salmeterol xinafo-ate/fluticasone propionate dry powder combination product via Diskus inhaler improves asthma control compared to salmeterol xinafoate or fluticasone propionate alone [abstract]//Am. J. Respir. Crit. Care Med.— 1998.— Vo.157, (Pt2) Suppl., P.A414.</mixed-citation><mixed-citation xml:lang="en">Edwards T., Gross G., Mitchell D., et al. The salmeterol xinafo-ate/fluticasone propionate dry powder combination product via Diskus inhaler improves asthma control compared to salmeterol xinafoate or fluticasone propionate alone [abstract]//Am. J. Respir. Crit. Care Med.— 1998.— Vo.157, (Pt2) Suppl., P.A414.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Eickelberg O., Roth M., Lorx R., et al. Ligand-independent actvation of the glucocorticoid receptor by p2-adrenergic receptor agonists in primary human lung fibroblasts and vascular smooth muscle cells//J. Biol. Chem.— 1999.— Vol.274, N.2.— P. 1005— 1010.</mixed-citation><mixed-citation xml:lang="en">Eickelberg O., Roth M., Lorx R., et al. Ligand-independent actvation of the glucocorticoid receptor by p2-adrenergic receptor agonists in primary human lung fibroblasts and vascular smooth muscle cells//J. Biol. Chem.— 1999.— Vol.274, N.2.— P. 1005— 1010.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Green S.A., Spasoff A.P., Coleman R.A., et al. Sustained activation of a G protein-coupled receptor via 'anchored' agonist binding. Molecular localization of the salmeterol exosite within the p2-adrenergic receptor//J. Biol. Chem. 1996.— P. 2429—2435.</mixed-citation><mixed-citation xml:lang="en">Green S.A., Spasoff A.P., Coleman R.A., et al. Sustained activation of a G protein-coupled receptor via 'anchored' agonist binding. Molecular localization of the salmeterol exosite within the p2-adrenergic receptor//J. Biol. Chem. 1996.— P. 2429—2435.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Greening A.P., Ind P.W., Northfield M., Allen&amp;Hanburys Limited UK Study Group, et al. Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid//Lancet.— 1994.— Vol.344, №.8917.— P. 219—224.</mixed-citation><mixed-citation xml:lang="en">Greening A.P., Ind P.W., Northfield M., Allen&amp;Hanburys Limited UK Study Group, et al. Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid//Lancet.— 1994.— Vol.344, №.8917.— P. 219—224.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Holliday S.M ., Faulds D., Sorkin L.M. Inhaled fluticasone propionate: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in asthma//Drugs.— 1994.— Vol.47.— P.318— 331.</mixed-citation><mixed-citation xml:lang="en">Holliday S.M ., Faulds D., Sorkin L.M. Inhaled fluticasone propionate: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in asthma//Drugs.— 1994.— Vol.47.— P.318— 331.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Ind P.W., Dal Negro R., Colman N., et al. Inhaled fluticasone propionate and salmeterol in moderate adult asthma II: exacerbations [abstract]// Am. J. Respir. Crit. Care Med.— 1998.— Vol.157 (Pt2), Suppl.— P. A415.</mixed-citation><mixed-citation xml:lang="en">Ind P.W., Dal Negro R., Colman N., et al. Inhaled fluticasone propionate and salmeterol in moderate adult asthma II: exacerbations [abstract]// Am. J. Respir. Crit. Care Med.— 1998.— Vol.157 (Pt2), Suppl.— P. A415.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Ind P.W., Dal Negro R., Colman N., et al. Inhaled fluticasone propionate and salmeterol in moderate adult asthma I: lung function and symptoms [abstract]// Am. J. Respir. Crit. Care Med.— 1998.— Vol.157, (Pt2), Suppl.— P.A416.</mixed-citation><mixed-citation xml:lang="en">Ind P.W., Dal Negro R., Colman N., et al. Inhaled fluticasone propionate and salmeterol in moderate adult asthma I: lung function and symptoms [abstract]// Am. J. Respir. Crit. Care Med.— 1998.— Vol.157, (Pt2), Suppl.— P.A416.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Jack D. The use of inhaled p2 adrenergic hronchodilators and anti-inflammatory steroids in asthma// J. Pharmaceut. Med.— 1996.— Vol.6, №.1— 2.— P.5— 16.</mixed-citation><mixed-citation xml:lang="en">Jack D. The use of inhaled p2 adrenergic hronchodilators and anti-inflammatory steroids in asthma// J. Pharmaceut. Med.— 1996.— Vol.6, №.1— 2.— P.5— 16.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Jarvis B., Faulds D. Inhaled fluticasone propionate: a review of its therapeutic efficacy at dosages &lt;500 meg/day in adults and adolescents with mild to moderate asthma// Drugs.— 1999.— Vol.57.— P.769— 803.</mixed-citation><mixed-citation xml:lang="en">Jarvis B., Faulds D. Inhaled fluticasone propionate: a review of its therapeutic efficacy at dosages &lt;500 meg/day in adults and adolescents with mild to moderate asthma// Drugs.— 1999.— Vol.57.— P.769— 803.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Johnson M. Development of fluticasone propionate and comparison with other inhaled corticosteroids// J. Allergy Clin. Immunol.— 1998.— Vol.101, (Part 2) Suppl.— P. 434—439.</mixed-citation><mixed-citation xml:lang="en">Johnson M. Development of fluticasone propionate and comparison with other inhaled corticosteroids// J. Allergy Clin. Immunol.— 1998.— Vol.101, (Part 2) Suppl.— P. 434—439.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Kalberg J.C., Yancey S., Emmett A.H., et al. A comparison of salmeterol versus zafirlucast in patients using inhaled corticosteroids [abstract]// J. Allergy Clin. Immunol.— 1999.— Vol.103.— P.S229.</mixed-citation><mixed-citation xml:lang="en">Kalberg J.C., Yancey S., Emmett A.H., et al. A comparison of salmeterol versus zafirlucast in patients using inhaled corticosteroids [abstract]// J. Allergy Clin. Immunol.— 1999.— Vol.103.— P.S229.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Lumry W., Windom H., Mendelson L., et al. The salmeterol/fluticasone propionate (50/250mcg) dry powder combination Diskus has a faster onset of effect compared with salmeterol or fluticasone propionate in patients with asthma// J. Allergy Clin. Immunol.— 1999.— Vol. 103, Pt2.— P.132.</mixed-citation><mixed-citation xml:lang="en">Lumry W., Windom H., Mendelson L., et al. The salmeterol/fluticasone propionate (50/250mcg) dry powder combination Diskus has a faster onset of effect compared with salmeterol or fluticasone propionate in patients with asthma// J. Allergy Clin. Immunol.— 1999.— Vol. 103, Pt2.— P.132.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">National Institutes of Health. Global initiative for asthma. Global strategy for asthma management and prevention N H LB/ WHO workshop report [online]. Global Initiative for Asthma and National Heart, Lung and Blood Institute; 1995 Jan. Available from: URL: http://www.ginasthma.com/workshop/default.html [Accessed 1999 May 5].</mixed-citation><mixed-citation xml:lang="en">National Institutes of Health. Global initiative for asthma. Global strategy for asthma management and prevention N H LB/ WHO workshop report [online]. Global Initiative for Asthma and National Heart, Lung and Blood Institute; 1995 Jan. Available from: URL: http://www.ginasthma.com/workshop/default.html [Accessed 1999 May 5].</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Pieters W.R., Steinmetz K.O., Aubier М., et al. Effectiveness of a new salmeterol/fluticasone propionate (50/500 meg) combination inhaler in patients with reversible airways obstruction [abstract]// Eur. Respir. J.— 1998.— Vol. 12, Suppl. 28.— P. 35s.</mixed-citation><mixed-citation xml:lang="en">Pieters W.R., Steinmetz K.O., Aubier М., et al. Effectiveness of a new salmeterol/fluticasone propionate (50/500 meg) combination inhaler in patients with reversible airways obstruction [abstract]// Eur. Respir. J.— 1998.— Vol. 12, Suppl. 28.— P. 35s.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Reese P.R., Mahajan P., Woodring A. Salmeterol/fluticasone pro-pionate combination product improves quality of life in asthma patients [abstract]// Eur. Respir. J.— 1998.— Vol.12, Suppl. 28.— P.35s.</mixed-citation><mixed-citation xml:lang="en">Reese P.R., Mahajan P., Woodring A. Salmeterol/fluticasone pro-pionate combination product improves quality of life in asthma patients [abstract]// Eur. Respir. J.— 1998.— Vol.12, Suppl. 28.— P.35s.</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Reese P.R., Mather D.B., Mahajan P., et al. Combination of salmeterol/ flutica-sone propionate via Diskus improves quality of life in asthma patients [abstract]//J. Allergy Clin. Immunol.— 1999.— Vol.103, Pt2.— P.69.</mixed-citation><mixed-citation xml:lang="en">Reese P.R., Mather D.B., Mahajan P., et al. Combination of salmeterol/ flutica-sone propionate via Diskus improves quality of life in asthma patients [abstract]//J. Allergy Clin. Immunol.— 1999.— Vol.103, Pt2.— P.69.</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Seretide. Monograph. Glaxo Wellcome UK. 1998.</mixed-citation><mixed-citation xml:lang="en">Seretide. Monograph. Glaxo Wellcome UK. 1998.</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Sly R.M. New guidelines for diagnosis and management of asthma/ / Ann. Allergy Asthma Immunol.— 1997.— Vol.78.— P.427—437.</mixed-citation><mixed-citation xml:lang="en">Sly R.M. New guidelines for diagnosis and management of asthma/ / Ann. Allergy Asthma Immunol.— 1997.— Vol.78.— P.427—437.</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Verberne A.A.P.H., Frost C., Duiverman E.J., et al. Addition of salmeterol versus doubling the dose of beclamethasone in children with asthma// Am. J. Respir. Crit. Care Med.— 1998 Vol.158.— P.213— 219.5p</mixed-citation><mixed-citation xml:lang="en">Verberne A.A.P.H., Frost C., Duiverman E.J., et al. Addition of salmeterol versus doubling the dose of beclamethasone in children with asthma// Am. J. Respir. Crit. Care Med.— 1998 Vol.158.— P.213— 219.5p</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Woolcock A., Lundback B., Ringdal N., et al. Comparison of addition of salmeterol to inhaled steroids with doubling of the dose of inhaled steroids// Am. J. Respir. Crit. Care Med.— 1996.— Vol.153, N.5.— P.1481 — 1488.</mixed-citation><mixed-citation xml:lang="en">Woolcock A., Lundback B., Ringdal N., et al. Comparison of addition of salmeterol to inhaled steroids with doubling of the dose of inhaled steroids// Am. J. Respir. Crit. Care Med.— 1996.— Vol.153, N.5.— P.1481 — 1488.</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Zimmerman B., Gold М., Wherrett D., et al. Adrenal suppression in two patients with asthma treated with low doses of the inhaled steroid fluticasone propionate// J. Allergy Clin. Immunol.— 1998.— Vol.101.— P.425— 426.</mixed-citation><mixed-citation xml:lang="en">Zimmerman B., Gold М., Wherrett D., et al. Adrenal suppression in two patients with asthma treated with low doses of the inhaled steroid fluticasone propionate// J. Allergy Clin. Immunol.— 1998.— Vol.101.— P.425— 426.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
